TB/FLU-01L
Candidate Overview
Replication-deficient recombinant influenza virus A expressing ESAT-6 antigen.
Sponsor / Lead Developer: Research Institute for Biological Safety Problems (RIBSP)
Development partner(s): Smorodintsev Research Institute of Influenza (SRII)
Clinical Trials
COMPLETED TRIALS |
|
| Registry Number | NCT03017378 |
| Clinical Trial Phase | Phase 1 |
| Status | Completed |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
Additional Information
Phase 1 trial planned for 2023.